2016
DOI: 10.5958/0974-360x.2016.00444.3
|View full text |Cite
|
Sign up to set email alerts
|

Development and validation of a chromatographic method for the estimation of rifampicin in bulk and pharmaceutical formulations

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2021
2021
2022
2022

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(1 citation statement)
references
References 0 publications
0
1
0
Order By: Relevance
“…H451Y and S456L mutants have increased their binding energy respectively to -7.3 kcal/ mol and -8.2 kcal/mol compared to native protein (Table 1). Both of these variants have been confirmed to be resistant to rifampicin [39][40][41] . In another study also found the difference of binding energies observed in the docking study, evidently that RMP is less effective in the treatment of patients with S425L variant 20 .…”
Section: Resultsmentioning
confidence: 93%
“…H451Y and S456L mutants have increased their binding energy respectively to -7.3 kcal/ mol and -8.2 kcal/mol compared to native protein (Table 1). Both of these variants have been confirmed to be resistant to rifampicin [39][40][41] . In another study also found the difference of binding energies observed in the docking study, evidently that RMP is less effective in the treatment of patients with S425L variant 20 .…”
Section: Resultsmentioning
confidence: 93%